

February 2, 2026

The Manager – Listing
BSE Limited
1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sir(s),

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Disclosure of ESG Rating

We wish to inform you that SES ESG Research Private Limited (SES) has, vide its Environmental, Social, and Governance (ESG) Report as received by AstraZeneca Pharma India Limited ('the Company') on January 30, 2026, assigned an ESG Score (Adjusted) as 64.4 (Grade B) based on publicly available information pertaining to FY 2024-25.

Please note that the Company has not engaged SES for ESG Rating. SES has independently prepared the report based on publicly available information for FY 2024-25.

This intimation is in compliance with Regulation 30 of SEBI Listing Regulations read with the SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Further, the aforementioned report was accessed on February 2, 2026 and some time was spent in good faith for evaluation of the contents laid in the report.

Kindly take the above information on record.

Thanking you,

For **AstraZeneca Pharma India Limited**

Bhavana Agrawal
Chief Financial Officer & Director

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628